» Articles » PMID: 23778059

HIV-infected Adolescent, Young Adult and Pregnant Smokers: Important Targets for Effective Tobacco Control Programs

Overview
Publisher MDPI
Date 2013 Jun 20
PMID 23778059
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Tobacco use is inextricably linked to a number of health risks both in the general and HIV-infected populations. There is, however, a dearth of research on effective tobacco control programs among people living with HIV, and especially among adolescents, young adults and pregnant women, groups with heightened or increased vulnerability secondary to tobacco use. Adolescents and young adults constitute a growing population of persons living with HIV infection. Early and continued tobacco use in this population living with a disease characterized by premature onset multimorbidity and chronic inflammation is of concern. Additionally, there is an increased acuity for tobacco control among HIV-infected pregnant women to reduce pregnancy morbidity and improve fetal outcome. This review will provide an important summary of current knowledge of tobacco use among HIV-infected adolescents, young adults and pregnant women. The effects of tobacco use in these specific populations will be presented and the current state of tobacco control within these populations, assessed.

Citing Articles

"You Almost Feel Out of Touch [For Saying] … 'Oh, and by the way, Stop Smoking.'" A Qualitative Exploration of Provider Perspectives About Discussing Tobacco and Cannabis Use With 18-24-Year-Old Young Adults With HIV.

Hill S, Palenski P, Crane H, OCleirigh C, Matthews L, Cropsey K J Int Assoc Provid AIDS Care. 2023; 22:23259582231163125.

PMID: 37009663 PMC: 10074605. DOI: 10.1177/23259582231163125.

References
1.
Niaura R, Chander G, Hutton H, Stanton C . Interventions to address chronic disease and HIV: strategies to promote smoking cessation among HIV-infected individuals. Curr HIV/AIDS Rep. 2012; 9(4):375-84. PMC: 3566982. DOI: 10.1007/s11904-012-0138-4. View

2.
Faessel H, Ravva P, Williams K . Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2009; 31(1):177-89. DOI: 10.1016/j.clinthera.2009.01.003. View

3.
Ostrowski S, Katzenstein T, Pedersen B, Gerstoft J, Ullum H . Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers. Scand J Immunol. 2008; 68(6):652-60. DOI: 10.1111/j.1365-3083.2008.02184.x. View

4.
Connor E, Sperling R, Gelber R, Kiselev P, Scott G, OSullivan M . Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994; 331(18):1173-80. DOI: 10.1056/NEJM199411033311801. View

5.
Pedrol-Clotet E, Deig-Comerma E, Ribell-Bachs M, Vidal-Castell I, Garcia-Rodriguez P, Soler A . [Bupropion use for smoking cessation in HIV-infected patients receiving antiretroviral therapy]. Enferm Infecc Microbiol Clin. 2006; 24(8):509-11. DOI: 10.1157/13092468. View